Liraglutide is a glucagon-like-peptide-1 receptor agonist (GLP-1-RA) and is FDA-approved for type 2 diabetes as liraglutide 1.8mg and for obesity as liraglutide 3.0mg. This evidence concerns the gene GLP1R and Obesity.